Meeting
2024 ASCO Annual Meeting
Development of NTX-472, a formulated mRNA therapy targeting CD20, CD19, and CD47, for treatment of B-cell lymphoma.
Authors
Adrienne Sallets
Nutcracker Therapeutics, Emeryville, CA
Adrienne Sallets , Weiqun Liu , Shruti Lal , Gowrisudha Adusumilli , Anushtha Sharma , Srinivasa Bandi , Pragyesh Dhungel , Kimmy Ferry , Ray Low , Pei-Ken Hsu , Evan McCartney-Melstad , Meredith Leong , Colin Mckinlay , Samuel Deutsch , Ole Haabeth , Gunasekaran Kannan
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics—Immunotherapy
Sub Track
Antibodies
Citation
J Clin Oncol 42, 2024 (suppl 16; abstr 2537)
DOI
10.1200/JCO.2024.42.16_suppl.2537
Abstract #
2537
Poster Bd #
16
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Association of peripheral memory B cell population maintenance and long term survival after perioperative chemoimmunotherapy in NSCLC (NADIM trial).
First Author: Belen Sierra-Rodero
Poster
2023 ASCO Annual Meeting
Preliminary results from a phase I/II study of IMM0306, a CD47 and CD20 bispecific monoclonal antibody-trap, in patients with relapsed or refractory CD20-positive B-cell non-Hodgkin's lymphoma.
First Author: Jianliang Yang
Poster
2023 ASCO Annual Meeting
Updated clinical results of first-in-human study of CD19/BCMA dual-targeting fast CAR-T GC012F for patients with relapsed/refractory B-cell non-Hodgkin’s lymphoma.
First Author: Xinfeng Chen
Poster
2021 ASCO Annual Meeting
A phase 3 study to evaluate the efficacy and safety of tafasitamab plus lenalidomide and rituximab versus placebo plus lenalidomide and rituximab in patients with relapsed/refractory (R/R) follicular lymphoma (FL) or marginal zone lymphoma (MZL).
First Author: Laurie Helen Sehn